HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium.

AbstractBACKGROUND:
We recently reported on novel vitamin D receptor (VDR) modulators that are structurally distinct from the secosteroid 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), the endogenous activator of VDR. One of these compounds, LG190119, was tested for the ability to inhibit the growth of LNCaP human prostate cancer cell-derived tumors in athymic mice.
METHODS:
In one study, athymic mice with established LNCaP xenograft tumors were dosed orally every day with LG190119 (3 or 10 mg/kg) or with a synthetic analog of 1,25(OH)(2)D(3), EB1089 (1 microg/kg), for 15 days. In another study ("prevention mode"), oral administration (every other day) of 10 mg/kg LG190119 or a non-hypercalcemic dose of 1,25(OH)(2)D(3) (0.5 microg/kg) was initiated prior to tumor development and continued for 84 days. In both studies, tumor volumes, mouse weights, and serum calcium levels were measured.
RESULTS:
In the established tumor study, LG190119 at each dose resulted in significant tumor growth inhibition without hypercalcemia at both 10 and 15 days. EB1089 treatment resulted in significant tumor growth inhibition only at Day 10 and resulted in hypercalcemia at Day 15. In the prevention-mode study, LG190119 markedly slowed tumor growth without increased serum calcium in comparison with either vehicle or 1,25(OH)(2)D(3) treatment (P < 0.001).
CONCLUSIONS:
LG190119 effectively inhibited LNCaP xenograft tumor growth without increased serum calcium levels or any other apparent side effects. Compounds of this class may represent promising new therapeutics for treatment of prostate cancer and other cancers with fewer undesirable side effects than currently used drugs.
AuthorsT C Polek, S Murthy, S E Blutt, M F Boehm, A Zou, N L Weigel, E A Allegretto
JournalThe Prostate (Prostate) Vol. 49 Issue 3 Pg. 224-33 (Nov 01 2001) ISSN: 0270-4137 [Print] United States
PMID11746268 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
CopyrightCopyright 2001 Wiley-Liss, Inc.
Chemical References
  • Antineoplastic Agents
  • Biphenyl Compounds
  • Growth Inhibitors
  • Ketones
  • LG 190119
  • Receptors, Calcitriol
  • Calcium
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Biphenyl Compounds (pharmacology)
  • Body Weight
  • Calcium (blood)
  • Cell Division (drug effects)
  • Growth Inhibitors (pharmacology)
  • Humans
  • Ketones (pharmacology)
  • Male
  • Mice
  • Mice, Nude
  • Prostatic Neoplasms (blood, drug therapy, pathology, prevention & control)
  • Random Allocation
  • Receptors, Calcitriol (agonists)
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: